Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04127578 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 15, 2019
Last Update Posted : July 5, 2022
|
Sponsor:
Prevail Therapeutics
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Prevail Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | April 2028 |
| Estimated Study Completion Date : | April 2028 |